pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,180 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace295Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7391Rare Disease1830Cardiology1673Immunology1467Hematology1302Vaccines1180Pulmonology
  • Specialized logistics critical for delivering next-generation cell and gene therapies
    The article explains that personalized medicines such as cell and gene therapies are transforming treatment for rare diseases and cancers. Unlike conventional drugs, these therapies are often made…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Biopharma capacity crunch shifts focus to ready-now manufacturing hubs like Middlesex County, NJ
    Demand for biopharma manufacturing, especially cell and gene therapies, is growing faster than the ability to build new GMP-ready facilities, which can take years to complete. To keep pace, compan…
    BioPharma Dive · 3mo agoNeutral↗ source
← prev
page 43 of 48
next →
fda recalls67
fda medwatch60
fda press38
1087
Psychiatry & CNS860
Ophthalmology492
Pain470
Endocrinology & Metabolism466
Infectious Disease439
Experts highlight growing role of treatment intensification for metastatic castration-sensitive prostate cancer
During an OncLive Peer Exchange, prostate-cancer specialists examined how treatment intensification is reshaping management of metastatic castration-sensitive prostate cancer. They noted that andr…
onclive · 3mo agoNeutral↗ source
  • Experts discuss when to start therapy for pediatric low‑grade glioma, weighing chemo, MEK inhibitors and family factors
    In a recent discussion, pediatric neuro‑oncologists examined how to decide when to begin treatment for low‑grade glioma in children. They highlighted the need to balance chemotherapy and MEK inhibi…
    onclive · 3mo agoNeutral↗ source
  • Dr Randall explains rationale for CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor trial
    Dr Randall, a professor at UC Davis Comprehensive Cancer Center, discussed the clinical reasoning behind testing the selective CSF-1R inhibitor pimicotinib (ABSK021) for tenosynovial giant cell tum…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss how real-world patient factors shape first-line renal cell carcinoma treatment choices
    Dr. Elizabeth Plimack and Dr. Yasser Ged appeared in a recent segment to talk about first-line treatment selection for renal cell carcinoma. They explained that beyond clinical trial results, real…
    onclive · 3mo agoNeutral↗ source
  • Clinicians balance symptoms, MRI changes and family goals when deciding treatment for pediatric low-grade glioma, beyond size criteria
    In a recent discussion, pediatric neuro‑oncology experts examined how they apply the RAPNO criteria to assess low‑grade gliomas in children. They highlighted that treatment decisions often go beyon…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss practical treatment selection for renal cell carcinoma across risk groups
    A recent educational segment featured Dr. Elizabeth Plimack together with Dr. Sundhar Ramalingam and Dr. Yasser Ged discussing treatment choices for renal cell carcinoma. The conversation centered…
    onclive · 3mo agoNeutral↗ source
  • MimiVax and Roswell Park start Phase 2 trial of SurVaxM with temozolomide for metastatic neuroendocrine tumors
    MimiVax Inc. and Roswell Park Comprehensive Cancer Center announced the launch of a randomized Phase 2 study evaluating SurVaxM in combination with temozolomide for patients with progressing metast…
    onclive · 3mo agoCRLNeutral↗ source
  • Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
    Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
    onclive · 3mo agoNeutral↗ source
  • Nivolumab added to standard radiation and hormone therapy yields 90% two-year disease control in high-risk prostate cancer
    A Phase 2 trial evaluated the combination of nivolumab with standard radiation and hormone therapy in patients with high‑volume grade group 5 prostate cancer. The study reported a 2‑year freedom f…
    onclive · 4mo agoPositive readoutPositive↗ source
  • OncLive highlights key advances in ovarian, Hodgkin lymphoma, pancreatic, melanoma and myelofibrosis therapies
    The weekly "Five Under 5" roundup from OncLive curates the most notable oncology video content released during the first week of May. It spotlights recent data across a range of cancer types, offer…
    onclive · 4mo agoNeutral↗ source
  • FDA approves zenocutuzumab for previously treated NRG1-fusion cholangiocarcinoma
    The FDA has granted approval for zenocutuzumab to treat patients with previously treated, advanced cholangiocarcinoma that carries an NRG1 fusion. The decision was based on data from the eNRGy stud…
    onclive · 4mo agoApprovalPositive↗ source
  • Antibody-drug conjugates poised to move lung cancer treatment earlier, boosting response rates and targeting brain metastases
    Experts highlight that antibody‑drug conjugates are reshaping non‑small cell lung cancer therapy, moving beyond their traditional role in later‑line settings. The new agents have demonstrated high…
    onclive · 4mo agoPositive↗ source
  • Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trial
    Dr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Sacituzumab Govitecan-Trastuzumab Combo Shows Low Response in HER2-Positive Metastatic Breast Cancer After T-DXD
    The phase 2 SATEEN trial evaluated sacituzumab govitecan combined with trastuzumab in patients with HER2-positive metastatic breast cancer who had progressed on T-DXD. The study enrolled 27 evalua…
    onclive · 4mo agoNegative readoutNegative↗ source
  • Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
    Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.
    onclive · 4mo ago↗ source
  • Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
    Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.
    onclive · 4mo ago↗ source
  • Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
    Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.
    onclive · 4mo ago↗ source
  • FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
    onclive · 4mo ago↗ source
  • UT MD Anderson Shares Latest Research Breakthroughs
    The University of Texas MD Anderson Cancer Center released recent oncology research highlights.
    onclive · 4mo ago↗ source
  • Lilly to invest extra $4.5B across Indiana manufacturing
    The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.
    BioPharma Dive · 4mo ago↗ source
  • Giants of Cancer Care Announces the 14th Annual Class of Inductees
    onclive · 4mo ago↗ source
  • OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
    Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
    onclive · 4mo ago↗ source
  • OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
    Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
    onclive · 4mo ago↗ source